Wilson Sonsini Goodrich & Rosati represented Impossible Foods in the case. Impossible Foods secured a victory in a patent infringement litigation that Impossible filed against Motif...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction. Halia Therapeutics announced it raised $30 million in Series C financing round led by Todd Pedersen, with continued...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising K18 on the transaction. Unilever announced it signed an agreement to acquire premium biotech haircare brand K18. Founded in 2020...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Khosla Ventures on the transaction. Vivodyne announced the close of $38 million in total seed financing, led by Khosla Ventures, with...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati provided IP and corporate counsel to DermBiont in the transaction. DermBiont announced its $35.2 million Series B financing. The financing was led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction. Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk advised the representatives of the underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal. Janux Therapeutics, a developer of safe, effective novel immunotherapies using its proprietary Tumor Activated T...
You must be a Standard 1 Year member to access this content.
